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Heterogeneous ampliﬁcation of ERBB2 in primary lesions is responsible for the discordant
ERBB2 status of primary and metastatic lesions in gastric carcinoma
Aims: To determine the extent of HER2 homogene-
ity ⁄ heterogeneity in primary versus metastatic gastric
carcinoma (GC).
Materials and results: The human epidermal growth
factor receptor 2 (HER2) status in primary and meta-
static lesions was evaluated by immunohistochemistry
(IHC) and ﬂuorescencein-situhybridization (FISH). Four
separate cohorts consisting of primary GC alone or
primary GC paired with metastatic lesions were exam-
ined. In the FISH analysis of 325 primary GCs, eight
cases(2.5%)showedampliﬁcationwithaheterogeneous
pattern, whereas 27 cases (8.3%) showed ampliﬁcation
with a homogeneous pattern, and in this cohort the
discordant:concordant FISH ratio based on examination
of three different areas in each primary lesion was
0.30:1. FISH testing using 250 paired primary and
metastatic lesions revealed seven cases (2.8%) with
discordant ampliﬁcation. In metastatic disease positive
conversion occurred in six cases (2.4%), whereas neg-
ative conversion happened in one case (0.4%). The
discordant:concordant ratio of primary versus second-
arylesionswas0.23:1.Whenthesevendiscordantcases
were re-evaluated using whole sections of primary GCs,
six showed a heterogeneous pattern of ampliﬁcation.
Conclusions: These ﬁndings suggest that the discor-
dant HER2 ampliﬁcation observed in metastatic lesions
is explained substantially by heterogeneity within
primary tumours.
Keywords: ﬂuorescence in-situ hybridization, HER2, immunohistochemistry, stomach neoplasm, tissue array analysis
Abbreviations: FISH, ﬂuorescence in-situ hybridization; GC, gastric carcinoma; HER2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry
Introduction
The HER2 (ERBB2) gene encodes a 185 kDa trans-
membrane tyrosine kinase receptor (p185), which is a
member of the epidermal growth factor receptor
family.
1,2 In breast carcinoma, HER2 ampliﬁcation is
observed in 15–30% of cases and is known to be
associated with adverse clinicopathological features
and outcomes.
3 In addition, human epidermal growth
factor receptor 2 (HER2) is a powerful predictive
marker of therapy based on the targeted HER2
inhibitor, trastuzumab.
4–7 Conversely, in gastric car-
cinoma (GC), the frequency of HER2 ampliﬁcation has
been reported variously to range from 7.7% to 27%,
and this ampliﬁcation has been established to corre-
late with an intestinal-type histology and poor
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7–11 HER2-positive GC might also be a
potential target for anti-HER2 therapy. Recently, the
ﬁrst randomized Phase III trial [Trastuzumab for
GAstric cancer (ToGA)] showed that trastuzumab
in combination with conventional chemotherapy is
superior to conventional chemotherapy alone in
HER2-positive advanced GC.
12 Therefore, an accurate
evaluation of HER2 status in GC has become increas-
ingly important.
In breast cancer, HER2 ampliﬁcation and expression
is highly homogeneous, although no consensus has
been reached as to whether HER2 status should be
assessed in primary or metastatic tissues for the
selection of patients for anti-HER2 therapy in the
metastatic setting. Although many studies have been
conducted to resolve this issue, opinions differ. Some
studies have shown good overall concordance between
primary and metastatic lesions, but others have dem-
onstrated high discordance rates.
13–19
In GC, HER2 heterogeneity has not been researched
extensively. In the literature, only one study has been
performed using 49 pairs of primary and metastatic
lymph node lesions, and the results obtained showed
that in all cases primary and metastatic lesions were
concordant by ﬂuorescence in-situ hybridization
(FISH).
20 In our previous study, a few cases demon-
strated heterogeneous staining in primary tumours,
e.g. focal positivity for HER2 protein, and in these cases
positive staining was observed in deeper portions or in
foci of lymphatic invasion.
8 In a separate experiment,
discrepant HER2 staining results were obtained for 222
paired primary GCs and metastatic lesions in lymph
nodes and in 3.6% of 222 cases, HER2 overexpression
was observed in metastatic lesions only (positive
conversion), and no case showed negative conver-
sion.
21 Although FISH was not performed, these
ﬁndings suggest that some GCs either gain HER2
copies during metastasis or that primary lesions have a
heterogeneous HER2 status.
InordertoexaminefurthertheheterogeneityofHER2
status between primary GC and metastatic lesions, 325
primary and 250 metastatic lesions were collected and
evaluated by immunohistochemistry (IHC) and FISH.
Materials and methods
patient samples
Four cohorts of tissue samples resected or biopsied at
Seoul National University Hospital between 1990 and
2006 were collected for analysis (Table 1). Cohort A
comprised 325 cases of primary GC that were resected
over 1 year (2004) – primary tumours of <3 cm were
excluded and three different areas were examined per
case; cohort B comprised 124 paired tissue samples of
synchronous metastatic carcinoma to regional lymph
nodes and primary GC tumours resected over 1 year
(2004); cohort C comprised 65 paired tissue samples of
synchronous distant metastasis and primary GC
tumours; and cohort D comprised 61 paired tissue
samples of metachronous distant metastasis and pri-
mary GC. Cohorts C and D were selected from archival
tissues collected between 1990 and 2006 by reviewing
medical and pathological records. Cases were enrolled if
paired primary and metastatic tissues were available for
IHC and FISH. Clinicopathological parameters, such as
age, sex, histological type, pathological stage and
interval of metastasis, were evaluated by reviewing
medical charts and pathological records. This study was
approved by the Institutional Review Board of Seoul
National University Hospital (H-0809-066-257).
slide preparation for evaluation of her2
Alltissuesampleswereﬁxedin10%bufferedformalinfor
24–48 h and then embedded in parafﬁn. Representative
cores (2 mm diameter) were taken from resected
primaryandmetastaticlesionsand34tissuemicroarray
Table 1. Four cohort populations prepared for the study
Cohort
Number
of cases
Examined
sections Description
A 325 975 Primary GC samples Examined three different areas per case
B 124 248 Paired samples Primary GC and synchronous metastatic carcinoma to regional lymph node
C 65 130 Paired samples Primary GC and synchronous metastatic carcinoma to distant site
D 61 122 Paired samples Primary GC and metachronous metastatic carcinoma to distant site
Total 575 1475
GC, Gastric carcinoma.
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(Superbiochips Laboratories, Seoul, Korea). Non-neo-
plastic gastric mucosa specimens were included in each
ofthearrayblocks,andthetissuearrayblockscontained
up to 60 cores. Small biopsy samples were evaluated
using whole sections.
immunohistochemistry
Immunohistochemistry was performed using a Leica
Bond-max automated immunostainer (Leica Microsys-
tems, Newcastle, UK), as described by the manufac-
turer’s protocol. In brief, formalin-ﬁxed, parafﬁn-
embedded, 4-lm sections were deparafﬁnized in a dry
oven, dewaxed in xylene and rehydrated through
graded alcohol. Heat pretreatment was performed
using citrate buffer (pH 6.0) at 100 C for 20 min.
Sections were then placed in an endogenous peroxide
block for 5 min, and anti-HER2 antibody (A0485,
rabbit polyclonal, 1:100; Dako, Carpenteria, CA, USA)
was then applied for 30 min. Antibody binding was
detected using a bond polymer reﬁne kit (Leica Micro-
systems) and diaminobenzidine tetrahydrochloride
solution (Kit HK153-5K; Biogenex, San Ramon, CA,
USA) was used as a chromogen.
HER2 immunostaining was scored in accordance
with the HER2 scoring system for GC (Hoffmann et al.’s
criteria).
22 This scoring system was applied to the tissue
array and full section samples. Four grading systems
were used: no membrane staining or membrane stain-
ing of <10% of tumour cells (score 0), faint ⁄ barely
perceptible partial membrane staining in >10% of
tumour cells (score 1+), weak to moderate staining of
the entire or basolateral membrane staining in >10% of
tumour cells (score 2+) and moderate to strong staining
of the entire or basolateral membrane in >10% of
tumour cells (score 3+). Biopsy samples with cohesive
clones are considered positive irrespective of size. Scores
of 0 and 1+ were considered negative and scores of 2+
and 3+ were considered positive (2 grading system).
fluorescence in-situ hybridization
Dual-colour PathVysion kits (Vysis, Downers Grove, IL,
USA) were used for FISH. Brieﬂy, slides of 2-lm-
sectioned deparafﬁnized and dehydrated slides were
incubated in 20% sodium bisulphate ⁄· 2 standard
saline citrate (·2 SSC) at 43 C for 20 min. After being
washed in ·2 SSC, slides were treated with proteinase K
at 37 C for 25 min. Denaturation, hybridization and
post-hybridization washing were carried out according
to the manufacturer’s instructions. Slides were then
counterstained with 4¢, 6-diamidine-2¢-phenylindole
dihydrochloride (DAPI) in anti-fade solution and exam-
ined under a ﬂuorescence microscope (Olympus,
Tokyo, Japan) equipped with Triple Bandpass Filter
Sets (Vysis). After counting at least 20 tumour cell
nuclei per slide, gene ampliﬁcation was deﬁned to be
present when the FISH ratio, HER2 signal (red) ⁄ cen-
tromere of chromosome 17 (green), was ‡2.0, as
described by the manufacturer.
Cases showing heterogeneous ampliﬁcation results of
the three cores of primary tumour (cohort A) and
primary and metastatic lesions (cohorts B, C and D)
were re-evaluated using multiple whole sections of all
available tumour tissues of parafﬁn blocks, including
the used tissue array blocks and the remaining
available blocks.
statistical analysis
Differences were compared using Fisher’s exact test or
Pearson’s v
2 test for non-continuous variables and
using Student’s t-test or analysis of variance for
continuous variables. Survival curves were estimated
using the Kaplan–Meier product–limit method and
signiﬁcant differences between survival curves were
determined using the log-rank test. All statistical tests
were two-sided, and statistical signiﬁcance was ac-
cepted for P-values <0.05. All analyses were performed
using SPSS version 17.0 (SPSS, Chicago, IL, USA).
Results
comparison of her2 status as evaluated by
ihc and fish in all cohorts
A total of 1475 different tumour areas were evaluated
for HER2 status (Table 1). Numbers of 0, 1+, 2+ and
3+ areas determined by IHC were 606 (41.1%), 474
(32.1%), 289 (19.6%) and 106 (7.2%), respectively
(Table 2); thus, HER2 overexpression was observed in
395 areas (26.8%). Using FISH, 160 areas (10.8%)
showed HER2 ampliﬁcation. None of the areas graded
as 0 by IHC showed ampliﬁcation by FISH, whereas all
3+ areas showed ampliﬁcation. Three of the 474 areas
(0.6%) graded 1+ by IHC were positive by FISH,
whereas 51 of the 289 areas (17.6%) graded 2+
showed ampliﬁcation. Furthermore, the correlation
between IHC and FISH results was statistically signif-
icant (P < 0.001).
Figure 1 shows a scatterplot between IHC grades and
FISH ratios in all 1475 different areas; IHC grades and
FISH ratios were found to be well correlated
(P < 0.001). For IHC grade 0, the FISH ratio was
1.09 ± 0.10, for grade 1+ the ratio 1.12 ± 0.20, for
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the ratio was 4.99 ± 1.14.
primary carcinomas examined in three
different areas (cohort a)
Of the 325 cases examined, signiﬁcant discordance in
HER2 protein overexpression between the three differ-
ent areas examined per sample was evident in 47 cases
(14.5%) (Table 3). Using FISH, eight of the 325 cases
(2.5%) showed discordant ampliﬁcation in different
areas and 27 cases (8.3%) showed concordant ampli-
ﬁcation in all three areas (Figure 2). Of the eight cases,
seven cases demonstrated concordant IHC expression
in three different areas, whereas one case demonstrated
discordant IHC expression. Accordingly, the discor-
dant:concordant ratio of FISH results in the three
different areas of primary carcinoma was 0.30:1.
Including homogeneously and heterogeneously
ampliﬁed cases, 35 cases had HER2 FISH-positive GC.
Table 4 summarizes clinicopathological differences
observed between primary GCs with or without HER2
ampliﬁcation. In particular, HER2 ampliﬁed GCs were
associated with the intestinal type of adenocarcinoma
by the Lauren classiﬁcation (P < 0.001). However, no
differences were observed between HER2 ampliﬁed and
non-ampliﬁed cases in terms of age, sex or pathological
stage. Kaplan–Meyer survival analysis also showed no
difference between HER2 ampliﬁed and non-ampliﬁed
cases (data not shown).
paired primary carcinomas and synchronous
regional lymph node metastasis (cohort b)
In total, 124 cases of paired primary GCs and syn-
chronous metastatic lesions in regional lymph node
tissues were included. Signiﬁcant discordances were
found between HER2 protein overexpression in pri-
mary and metastatic lesions in 27 cases (21.8%). Of
these 27 cases, 19 were negative for HER2 overexpres-
sion in primary lesions but showed HER2 overexpres-
sion in metastatic lymph nodes (positive conversion),
whereas eight cases showed overexpression in primary
lesions and no overexpression in metastatic lesions
(negative conversion).
Five cases (4.0%) analysed by FISH showed discor-
dance between primary and metastatic lesions
(Table 5, Figure 3). Of the ﬁve cases, four cases
demonstrated discordant IHC expression between the
primary and the metastatic lesion, whereas one case
demonstrated concordant IHC expression; four of these
ﬁve cases also showed positive conversion and one case
showed negative conversion. Twelve cases (9.7%)
showed concordant ampliﬁcation in primary and
metastatic lesions. To conﬁrm discordance, we per-
formed IHC using multiple whole sections of primary
Table 2. Comparison of HER2 status between immunohis-
tochemistry (IHC) and ﬂuorescence in-situ hybridization
(FISH) analysis in all different areas including cohorts A, B,
C and D
FISH
Not ampliﬁed Ampliﬁed Total
IHC
0 606 (100.0%) 0 (0.0%) 606
1+ 471 (99.4%) 3 (0.6%) 474
2+ 238 (82.4%) 51 (17.6%) 289
3+ 0 (0.0%) 106 (100.0%) 106
Total 1315 160 1475
P < 0.001 by Pearson’s v
2 test.
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Figure 1. Scatterplot between ERBB2 immunohistochemistry (IHC)
score and ﬂuorescence in-situ hybridization (FISH) ratio in all 1475
different areas. The IHC score and FISH ratio correlated well
(P < 0.001). All cases of IHC score 0 corresponded to FISH ratio <2.0,
whereas all cases of IHC score 3+ were equal to or more than 2.0.
Table 3. Summary of HER2 immunohistochemistry (IHC)
and ﬂuorescence in-situ hybridization (FISH) in three differ-
ent areas of primary gastric carcinomas (GCs) (cohort A)
IHC
overexpression
FISH
ampliﬁcation
None of three areas 220 (67.7%) 290 (89.2%)
One or two areas
(discordant)
47 (14.5%) 8 (2.5%)
All three areas
(concordant)
58 (17.8%) 27 (8.3%)
Total 325 325
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slide was then examined using multiple whole sections
of primary and metastatic lesions using the FISH
method. As a result, of the four that showed positive
conversion, three cases showed heterogeneous ampli-
ﬁcation in both primary and metastatic lesions, and the
remaining case was negative by FISH in the primary
lesion and positive in metastatic lymph nodes. In the
single case showing negative conversion the primary
lesion was ampliﬁed heterogeneously, whereas the
metastatic lesion was non-ampliﬁed homogeneously.
paired primary carcinomas and synchronous
distant metastasis (cohort c)
Sixty-ﬁve cases were included in this cohort. Metastasis
occurred predominantly in liver (54 cases); other sites
were the abdominal wall (four), supraclavicular lymph
node (two), mesentery (two), diaphragm (one), rectal
shelf(one)anduterus(one).Signiﬁcantdiscordancewas
observedbyIHCbetweenprimaryandmetastatic lesions
in eight cases (12.3%). One case showed positive
conversion and seven showed negative conversion.
Discrepant ampliﬁcation was observed in two cases
(3.1%), and both cases showed positive conversion
(Table 5). Of the two cases, one case demonstrated
discordant IHC expression between the primary and the
metastatic lesion, whereas one case demonstrated
concordant IHC expression. Ten cases (15.4%) showed
concordant ampliﬁcation in primary and metastatic
lesions. For the conﬁrmation of discordance, two
discordant cases were re-evaluated using multiple
whole sections of primary resected lesions using the
IHC method. Representative areas of each slide were
then examined using multiple whole sections of
primary lesions using the FISH method. As a result,
AB
CD
Figure 2. Heterogeneous ERBB2 status in different areas of the same primary tumour. ERBB2 protein expression evaluated by immunohis-
tochemistry (IHC) (A,C) and gene ampliﬁcation assessed by ﬂuorescence in-situ hybridization (FISH) (B,D). A,B, 0 by IHC staining without
ampliﬁcation; C,D, 3+ by IHC staining with ampliﬁcation.
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primary lesion. However, metastatic lesions could not
be evaluated fully because tissue samples were small
biopsy specimens.
paired primary carcinomas and
metachronous distant metastasis (cohort d)
Sixty-one cases were included in this cohort. Metastatic
sites were: liver (24 cases), abdominal wall (11),
intestine (nine), uterus (ﬁve), supraclavicular lymph
node (four), lung (two), breast (one) bone (one), skin
(one), urinary bladder (one), adrenal gland (one) and
gallbladder (one). The interval to proven metastasis
ranged from 6 to 84 months, median 25.7 months.
Using IHC, signiﬁcant discordance was observed
between primary and metastatic lesions in eight cases
(13.1%). Seven cases showed positive conversion and
one case negative conversion. Using FISH, nine cases
(14.8%) showed ampliﬁcation in both primary and
metastatic lesions and no discordance was found
between primary and metastatic lesions (Table 5).
summary of metastatic cases
In the present study, 250 metastatic lesions were
compared with the corresponding primary GCs (cohorts
B, C and D). IHC and FISH results were found to be well
correlated in primary as well as secondary lesions
(Table 6). In primary lesions, the ampliﬁcation rate of
cases with IHC grades 0, 1+, 2+ and 3+ was 0.0%,
2.8%, 17.6% and 100.0%, respectively, and in meta-
static lesions the ampliﬁcation rate of cases with IHC
scores of 0, 1+, 2+ and 3+ was 0.0%, 1.4%, 17.5% and
100.0%, respectively. Overall, 43 cases showed a
discordant IHC positivity result.
When these 250 cases were examined using FISH,
HER2 ampliﬁcation in primary GCs was detected in 32
(12.8%) and ampliﬁcation in metastatic lesions in 37
(14.8%) cases (Table 7). Seven of the 250 cases (2.8%)
showed discordant ampliﬁcation between primary and
secondary lesions and 31 (12.4%) cases showed
concordant ampliﬁcation, a discordant:concordant
ratio of 0.23:1. Of these seven discordant cases, two
cases showed a homogeneous IHC result, whereas ﬁve
cases showed a different, heterogeneous, IHC result.
The results of the re-evaluation conducted on whole
sections of seven discordant cases are summarized in
Table 8. Of the seven discordant cases, six showed
heterogeneous ampliﬁcation in the primary lesion and
of these six, three were heterogeneous, two were
positive and one was negative by FISH in the metastatic
lesion. The remaining case was negative by FISH in the
primary lesion, and positive in the metastatic lesion.
Table 4. Comparison of
clinicopathological ﬁndings
between HER2 ampliﬁed
and non-ampliﬁed primary
gastric carcinomas (GCs)
evaluated by ﬂuorescence
in-situ hybridization (FISH)
(cohort A)
HER2 FISH (n = 325)
None ampliﬁed in all
three areas (%) (n = 290)
Ampliﬁed in at least
one area (%) (n = 35)
P-value
Age (years) 58.2 ± 12.7 58.4 ± 11.9 NS
Sex
Male 206 (71.0) 28 (80.0) NS
Female 84 (29.0) 7 (20.0)
Lauren classiﬁcation
Intestinal 128 (44.1) 26 (74.3) <0.001
Diffuse 155 (53.4) 8 (22.9)
Mixed 7 (2.4) 1 (2.9)
Pathological stage
I 124 (42.8) 17 (48.6) NS
II 63 (21.7) 6 (17.1)
III 55 (19.0) 3 (8.6)
IV 48 (16.6) 9 (25.7)
NS, Not signiﬁcant.
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Heterogeneity of HER2 gene ampliﬁcation within a
tumour and between primary and paired metastatic
lesions is considered to be an important potential cause
of treatment failure by molecular analysis-based tar-
geted therapy in breast cancer. Some case reports have
demonstrated the heterogeneity of HER2 ampliﬁcation
in primary tumour, or discordant status between
primary and metastatic lesions with regard to trast-
uzumab therapy in breast cancer patients.
23,24 How-
ever, little is known of this topic in GC, although one
IHC study showed that heterogeneity in GC is greater
than that found in breast cancer.
22 To clarify this issue,
we collected 325 cases of primary GCs (cohort A) and
250 cases of metastatic carcinomas with their paired
primary carcinomas (cohort B, C and D) and performed
HER2 analysis by IHC and FISH.
Immunohistochemistry and FISH results in cohort A
corresponded well. Almost all primary tumours with an
IHC grade of 0 or 1+ showed no ampliﬁcation by FISH,
whereas all IHC 3+ cases showed ampliﬁcation. Of the
IHC 2+ cases, only about one-sixth showed HER2
ampliﬁcation. In this study, we used the HER2 scoring
for GC established by Hoffmann et al.
22 Our data
relationship is similar to this consensus meeting. Also,
Table 6. HER2 immunohistochemistry (IHC) and ﬂuores-
cence in-situ hybridization (FISH) results in 250 cases of
paired primary and secondary gastric carcinomas (GCs)
including cohorts B, C and D
IHC
Ampliﬁcation
Primary lesion Secondary lesion
00 ⁄ 106 (0.0%) 0 ⁄ 94 (0.0%)
1+ 2 ⁄ 72 (2.8%) 1 ⁄ 73 (1.4%)
2+ 9 ⁄ 51 (17.6%) 10 ⁄ 57 (17.5%)
3+ 21 ⁄ 21 (100.0%) 26 ⁄ 26 (100.0%)
Total 32 ⁄ 250 (12.8%) 37 ⁄ 250 (14.8%)
A
B
Figure 3. Discordant ampliﬁcation result of ERBB2 with ﬂuo-
rescence in-situ hybridization (FISH) analysis between primary and
metastatic lymph node tissue. A, Not ampliﬁed in primary lesion.
B, Ampliﬁed in metastatic lesion.
Table 5. Comparison of HER2 ﬂuorescence in-situ hybrid-
ization (FISH) result between primary gastric carcinomas
(GCs) and metastatic carcinomas (cohorts B, C and D)
Primary lesion
Non-ampliﬁed Ampliﬁed Total
Synchronous Lymph node Metastasis (cohort B)
Non-ampliﬁed 107 1 108
Ampliﬁed 4 12 16
Total 111 13 124
Synchronous Distant Metastasis (cohort C)
Non-ampliﬁed 53 0 53
Ampliﬁed 2 10 12
Total 55 10 65
Metachronous Distant Metastasis (cohort D)
Non-ampliﬁed 52 0 52
Ampliﬁed 0 9 9
Total 52 9 61
Sum (cohort B, C, D)
Non-ampliﬁed 212 1 213
Ampliﬁed 6 31 37
Total 218 32 250
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quality-controlled laboratories, and therefore the
American Society of Clinical Oncology ⁄ College of
American Pathologists Guidelines recommends that
FISH analysis be conducted on cases with an IHC 2+
lesion in breast cancer.
25 Furthermore, the concor-
dance between IHC and FISH results found in primary
gastric lesions was almost identical to that observed in
the metastatic tumours.
Fluorescence in-situ hybridization analysis in cohort
A showed that 35 cases (10.8%) demonstrated HER2
gene ampliﬁcation. Of these, 27 (8.3%) showed ampli-
ﬁcation with a homogeneous pattern, but eight (2.5%)
showed heterogeneous ampliﬁcation. Among the 325
cases of primary gastric carcinomas, 47 cases (14.5%)
showed different IHC positivity, whereas 278 cases
showed the same IHC positivity. Of the latter 278 cases,
only one case (0.34%) demonstrated a different FISH
result in three tissue array cores, while the remaining
277 cases showed the same FISH results in the three
cores. In contrast, seven cases (14.9%) of the 47 former
cases (heterogeneous IHC) demonstrated different FISH
results in the three cores. As a result, we feel that one
core or piece of biopsy is not sufﬁcient for examination
of positivity and ⁄ or ampliﬁcation. Therefore, we believe
that at least three different areas from the different
parafﬁn blocks should be examined in order to
overcome the heterogeneity in expression.
In addition, we compared the FISH results of primary
and secondary lesions; the latter were composed of
synchronous regional lymph node metastases (cohort
B), synchronous distant metastases (cohort C) and
metachronous distant metastases (cohort D). The FISH
results of metachronous distant metastatic lesions
agreed well with those of the primary lesions in all
patients. However, HER2 ampliﬁcation in primary and
secondary lesions was discordant in cohorts B and C in
different ways; that is, from no ampliﬁcation in primary
lesions to positive ampliﬁcation in secondary lesions,
and vice versa. Overall for metastatic cases, the
discordant:concordant ratio between primary and sec-
ondary lesions was 0.23:1, whereas the discor-
dant:concordant ratio between different areas in
primary tumours was 0.30:1. In other words, the
discordance rate of primary versus metastatic lesions
was no greater than the heterogeneous ampliﬁcation
rate within primary lesions. The incidence of discor-
dant ampliﬁcation for primary versus secondary lesions
was 2.8% (seven of 250 cases), while the incidence of
discordant ampliﬁcation in different areas of primary
lesions was 2.5% (eight of 325 cases). These ﬁndings
Table 8. Summary of dis-
cordant cases between pri-
mary and metastatic lesions
by ﬂuorescence in-situ
hybridization (FISH)
FISH in primary lesion
Homogeneously
ampliﬁed
Heterogeneously
ampliﬁed
Non-
ampliﬁed Total
FISH in metastatic lesion
Homogeneously ampliﬁed 0 2* 0 2
Heterogeneously ampliﬁed 0 3 1 4
Non-ampliﬁed 0 1 0 1
Total 0 6 1 7
*Analysis of primary lesion was performed in the whole section from resected specimens and
that of metastatic lesion in small biopsy specimens.
Table 7. Summary of HER2 ﬂuorescence in-situ
hybridization (FISH) in primary gastric carcinomas (GCs)
and metastatic carcinomas (cohorts B, C and D)
Cohort B C D Sum
Not ampliﬁed in any lesion 107 53 52 212 (84.8%)
Ampliﬁed in primary and ⁄
or secondary lesion
17 12 9 38 (15.2%)
Ampliﬁed in primary lesion 13 10 9 32 (12.8%)
Ampliﬁed in secondary lesion 16 12 9 37 (14.8%)
Concordant ampliﬁcation 12 10 9 31 (12.4%)
Discordant ampliﬁcation 5 2 0 7 (2.8%)
Positive conversion 4 2 0 6 (2.4%)
Negative conversion 1 0 0 1 (0.4%)
Total 124 65 61 250
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secondary lesions is the result of heterogeneity of
ampliﬁcation in primary lesions.
When we re-evaluated HER2 status using multiple
whole sections (average ﬁve slides per cases) of the
seven discordant cases, six showed heterogeneous
ampliﬁcation in the primary lesions. Only one case
showed a negative FISH result in the primary lesion,
but a positive FISH result in the metastatic lesion.
According to our data, the IHC result of whole sections
in the primary lesion and biopsy specimen were
comparable in most of the heterogeneous cases (six of
seven cases) expressed by FISH analysis. Therefore, we
believe that assessment of metastatic disease is compa-
rable to the primary lesion if the biopsy specimen is
sufﬁcient to overcome the heterogeneity of both lesions.
In metastatic lesions, positive conversion occurred in
2.4% and negative conversion in 0.4%, and although
positive conversion was higher than negative conver-
sion, the incidences of both were low. If it is presumed
that a subclone with HER2 ampliﬁcation has a
metastatic advantage, the positive conversion rate
should have been much higher than observed and
negative conversion should be non-existent. Accord-
ingly, our ﬁndings indicate that HER2 ampliﬁcation
promotes metastasis and recurrence only weakly. A
similar result was observed in a study using breast
cancer samples, in which of the 58 paired cases,
positive conversion was found in 12% of patients and
negative conversion in 2% only.
18 However, conﬂicting
results regarding discordant status in primary and
metastatic lesions have also been reported in breast
cancer. Gong et al.
16 found 98% and 94% concordance
between HER2 status in primary versus loco-regional
recurrent lesions and in primary versus distant meta-
static lesions, whereas Santinelli et al. evaluated HER2
status by IHC and FISH in primary and metastatic
lesions and found relatively few cases with discordant
status.
15 Furthermore, in one GC study, no discrepant
case was found by FISH between 49 paired primary
and lymph node metastasis lesions.
20 We believe that
these controversial results were probably due to the
small number of samples examined.
The present study was limited because we used a
tissue array, not whole sections. However, in clinical
practice IHC is usually performed on whole sections,
while FISH analysis is applied to a small (2–3 mm)
area. In this study, the IHC result was compared to the
FISH result and it seems incongruous that while FISH
was performed in a small area, the IHC study was
performed on the whole section. For this reason we
believe that using tissue arrays for the IHC study can
result in reasonable comparison data between IHC and
FISH. To overcome the inadequacy of the tissue array
method, we prepared multiple tissue array blocks from
three areas in every lesion. Furthermore, our tissue
array slides consisted of 2-mm-diameter individual
tumour tissue, which is a more than 10 times larger
area compared to the conventional 0.6-mm core.
In summary, we found discordant HER2 ampliﬁca-
tion in metastatic and primary lesions in 18.4% (seven
of 38) and discordant ampliﬁcation within primary
tumours in 22.9% of cases (eight of 35). Thus, we
believe that the discordant HER2 ampliﬁcation ob-
served in metastatic lesions is explained largely by
heterogeneity within the primary tumour. This study
also shows that IHC correlate well with FISH results. In
particular, none of the IHC grade 0 cases showed
ampliﬁcation whereas all IHC 3+ lesions showed
ampliﬁcation, and only about one-sixth of IHC 2+
cases showed HER2 gene ampliﬁcation. Therefore, we
recommend that IHC 2+ cases should be analysed by
FISH to determine HER2 gene ampliﬁcation in primary
and metastatic lesions.
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